US 12,290,566 B2
Dosing regimens and related compositions and methods
Federico Grossi, Needham, MA (US); Pascal Deschatelets, West Newton, MA (US); Cedric Francois, Prospect, KY (US); Patrick Johnson, Zurich (CH); and Carolina Vega, Berkeley, CA (US)
Assigned to Apellis Pharmaceuticals, Inc., Waltham, MA (US)
Filed by Apellis Pharmaceuticals, Inc., Waltham, MA (US)
Filed on Feb. 28, 2023, as Appl. No. 18/115,744.
Application 18/115,744 is a continuation of application No. 16/772,729, abandoned, previously published as PCT/US2018/065870, filed on Dec. 14, 2018.
Claims priority of provisional application 62/744,565, filed on Oct. 11, 2018.
Claims priority of provisional application 62/655,094, filed on Apr. 9, 2018.
Claims priority of provisional application 62/599,637, filed on Dec. 15, 2017.
Prior Publication US 2024/0115655 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 38/10 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/54 (2017.01); A61P 7/06 (2006.01); A61P 27/02 (2006.01); C07K 7/08 (2006.01)
CPC A61K 39/3955 (2013.01) [A61K 9/0019 (2013.01); A61K 38/10 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/54 (2017.08); A61K 47/542 (2017.08); A61P 7/06 (2018.01); A61P 27/02 (2018.01); C07K 7/08 (2013.01)] 20 Claims
 
1. A composition comprising:
(i) a long-acting compstatin analog (LACA) having a structure:

OG Complex Work Unit Chemistry
wherein the (CH2CH2O)n moiety has an average molecular weight of about 40,000 Daltons;
(ii) a pharmaceutically acceptable carrier; and
(iii) sorbitol,
wherein the pH of the composition is 5.0.